Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Press release: T-DXd + pertuzumab improved PFS vs THP in first-line HER2+ mBC. The T-DXd monotherapy arm remains blinded.
The PFS advantage with T-DXd+P is likely to be considerable. Enough to convince breast med oncs to drop the taxane induction strategy?”
More posts featuring Paolo Tarantino.